| Not Yet Recruiting | Predictive Value of Transcriptome-based OncoTreat/Oncotarget and Organoid Testing in Metastatic Pancreatic Can NCT06615830 | Prof. Dr. med. Dres. h.c. Jan Schmidt, MME | — |
| Recruiting | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Ad NCT07491445 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer NCT07049055 | Engeneic Pty Limited | Phase 1 / Phase 2 |
| Not Yet Recruiting | Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Lin NCT07342725 | Ruijin Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions NCT07230301 | Sizhen Wang | Phase 2 |
| Recruiting | Holistic Acupuncture for Patients With Chemotherapy Induced Nausea NCT07201194 | Vejle Hospital | N/A |
| Not Yet Recruiting | A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vacci NCT07231094 | The Third Xiangya Hospital of Central South University | EARLY_Phase 1 |
| Not Yet Recruiting | Influence of Metastatic Sites on Survival Outcomes and Predictive Factors for Extended Survival in Metastatic NCT07086352 | Assiut University | — |
| Recruiting | A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic C NCT07026279 | Amplia Therapeutics Limited | Phase 1 / Phase 2 |
| Recruiting | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients NCT06922591 | Tango Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Thi NCT07040228 | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic C NCT06916975 | Jin Xu | Phase 2 |
| Not Yet Recruiting | Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer. NCT06888648 | Zhejiang University | Phase 1 / Phase 2 |
| Recruiting | Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer. NCT06840067 | Gansu Wuwei Tumor Hospital | N/A |
| Recruiting | Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer NCT06752811 | Shanghai Yizhong Pharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdio NCT06946420 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 3 |
| Active Not Recruiting | The Seven Trial: Exploiting the Unfolded Protein Response NCT06076837 | HonorHealth Research Institute | Phase 1 |
| Recruiting | Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver NCT06690528 | Azienda Ospedaliera di Padova | Phase 2 |
| Recruiting | Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer NCT06605430 | HealthPartners Institute | Phase 2 |
| Recruiting | Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer NCT06030622 | State University of New York - Downstate Medical Center | Phase 1 / Phase 2 |
| Recruiting | A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatme NCT05969171 | Fudan University | Phase 2 |
| Active Not Recruiting | A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer NCT06168812 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan NCT06155136 | Servier Affaires Médicales | — |
| Withdrawn | Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancre NCT04799431 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Active Not Recruiting | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subj NCT05827614 | Boundless Bio, Inc. | Phase 1 |
| Active Not Recruiting | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) NCT05642962 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer NCT05254171 | Panbela Therapeutics, Inc. | Phase 2 / Phase 3 |
| Unknown | Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer NCT04667403 | Institut Cancerologie de l'Ouest | N/A |
| Recruiting | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep an NCT07280377 | Oncolytics Biotech | Phase 1 / Phase 2 |
| Unknown | Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients NCT05047991 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Safety Study of Whole Body Hyperthermia for Advanced Cancer NCT04467593 | ElmediX | N/A |
| Withdrawn | PanDox: Targeted Doxorubicin in Pancreatic Tumours NCT04852367 | University of Oxford | Phase 1 |
| Unknown | RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer NCT04338763 | Rise Biopharmaceuticals, Inc. | Phase 1 |
| Unknown | A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety o NCT04674956 | RenJi Hospital | Phase 3 |
| Completed | Pancreatic Adenocarcinoma Signature Stratification for Treatment NCT04469556 | University Health Network, Toronto | Phase 2 |
| Completed | INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampulla NCT04116073 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Adv NCT03984214 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Phase 3 |
| Completed | Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastati NCT03504423 | Cornerstone Pharmaceuticals | Phase 3 |
| Completed | Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer NCT03412799 | Panbela Therapeutics, Inc. | Phase 1 |
| Completed | Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE T NCT04721301 | University Hospital Heidelberg | Phase 1 |
| Unknown | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy NCT02959151 | Shanghai GeneChem Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma NCT01652976 | University of Florida | Phase 2 |
| Completed | Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cance NCT06921252 | Kochi University | — |
| Withdrawn | OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas NCT01600807 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |